Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.52 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.52 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.52 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001606 | 0.88 | CA2 (0.81) | CA2CA1ENPP2MGLLTSHR | |
| SCHEMBL21979751 | 0.85 | ORAI1 (0.68) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL5508 | 0.85 | ORAI1 (0.68) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL257626 | 0.85 | CA2 (0.59) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL18839425 | 0.83 | ORAI1 (0.65) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL8655522 | 0.82 | CA1 (0.46) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL257921 | 0.82 | CA1 (0.66) | CA2CA1ENPP2MGLLMEN1 | |
| SCHEMBL31558408 | 0.81 | CYP1A2 (0.49) | CA2CA1ORAI1ORAI2ORAI3 | |
| SCHEMBL5002492 | 0.81 | ENPP2 (0.55) | CA2CA1ENPP2MGLLMEN1 | |
| SCHEMBL6289867 | 0.80 | SOS1 (0.58) | SOS1HSPB1TSHRSCN4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4467539-A1 | OXAZOLE DERIVATIVE COMPOUND HAVING ANTIBACTERIAL ACTIVITY AND MEDICAL USE THEREOF | Institut Pasteur Korea (KR) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024137865-A1 | COMPOUNDS USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137865-A1 | COMPOUNDS USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-113149983-B | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-111454268-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116589465-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| EP-1432419-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2004-06-30 | — | — | EP | disclosed |
| EP-1004578-B1 | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. | 2003-03-20 | — | — | US | disclosed |
| WO-2003022276-A1 | ARYL SUBSTITUTED PYRIDINECARBOXAMIDES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2003-03-20 | — | — | WO | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
| US-6114361-A | INHIBITORS OF MATRIX METALLOPROTEINASES AND REPROLYSIN; ADMINISTERING TO TREAT CONDITIONS WHICH CAN BE TREATED BY THE INHIBITION OF THESE ENZYMES | PFIZER INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-1004578-A2 | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055088-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1D | CA2 2039/4885CA1 1272/4885ORAI1 426/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | CA2 2384/4885CA1 2012/4885ORAI1 691/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | CA2 3036/4885CA1 3395/4885ORAI1 2415/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | CA2 2384/4885CA1 2012/4885ORAI1 691/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | CA2 3685/4885CA1 4614/4885ORAI1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.